Phaseline

Companies › Shanghai IASO Biotechnology

Shanghai IASO Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Hematology, Immunology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IASO-782 injection–Phase 1SLE - Systemic Lupus Erythematosus; Autoimmune ThrombocytopeniaAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07483346IASO-782 injectionPhase 1SLE - Systemic Lupus ErythematosusImmunologyAug 2027
NCT06534021IASO-782 injectionPhase 1Autoimmune ThrombocytopeniaHematologyOct 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.